Research Perspective Volume 14, Issue 20 pp 8140—8149

Figure 3. Hypothetical rapamycin treatment in humans for maximal longevity. Started early in post-development (for example, at 21 yo), low doses of rapamycin decelerate progression of pre-diseases (slow aging). Side effects are more undesirable at younger ages and doses should be low. Doses are gradually increased, to avoid rapamycin adaptation and to maximize therapeutic potential.